
Senn Chemicals
Szwajcarski ośrodek badawczo-rozwojowy dotyczący peptydów i półproduktów peptydowych obejmujący SPPS, LPPS, syntezę hybrydową, zwiększanie skali laboratoryjnej
Services: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging
Region: Europe
Category / Product: COSMETICS, CHEMICAL-SYNTHETIC, SERVICES, PARTICLE ENGINEERING
Batch Size: Small

Senn Chemicals
Laboratorium peptydów GMP i syntezy organicznej na małą skalę do projektów klinicznych, niszowych i o wysokiej wartości, wymagających elastycznej produkcji cGMP
Services: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging
Region: Europe
Category / Product: CHEMICAL-SYNTHETIC, PARTICLE ENGINEERING
Batch Size: Small

Senn Chemicals
Zakład produkcyjny na dużą skalę niezgodny z GMP, zajmujący się półproduktami peptydowymi, syntezą organiczną, operacjami LPPS i produkcją na większą skalę.
Services: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging
Region: APAC
Batch Size: Large, Small, Medium
Category / Product: COSMETICS, CHEMICAL-SYNTHETIC, SERVICES, PARTICLE ENGINEERING

Senn Chemicals
Centrum badawczo-rozwojowe w dziedzinie chemii peptydów i organicznej z SPPS, oczyszczaniem, liofilizacją, analityką i wsparciem w zakresie inżynierii cząstek.
Services: Logistics, Development services, Analytical / QC services, Quality Assurance services, Packaging
Region: APAC
Category / Product: CHEMICAL-SYNTHETIC, PARTICLE ENGINEERING
Batch Size: Small

Polpharma API
Polpharma API to europejski CDMO oferujący małocząsteczkowe, oligonukleotydowe i łączniki ładunku do rozwoju i produkcji ADC
OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 5,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 5,000 µg/day)
Markets: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada)
Region: Europe
Compliance: FDA (cGMP), ISO, ANVISA (Brazil B-GMP), ECOVADIS, EMA (EU GMP), MFDS/KFDA (Republic of Korea GMP), ANVISA (Brazil)
Batch Size: Large, Small, Medium
Use: Human
Category / Product: OLIGONUCLEOTIDES, CHEMICAL-SYNTHETIC, SERVICES
Services: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services
Therapeutic Areas of Expertise (ATC): (C) Cardiovascular system, (M) Musculoskeletal system, (N) Nervous system, (A) Digestive tract and metabolism

VIVEbiotech
Twoje wiodące CDMO z certyfikatem GMP, przeznaczone wyłącznie do produkcji wektorów lentiwirusowych.
Markets: EMA (EU), FDA (USA), MHRA (UK)
Region: Europe
Compliance: FDA (cGMP), French Service-Public (CIR), EMA (EU GMP), MHRA (UK GMP)
Batch Size: Large, Small, Medium
Use: Human
BSL (Biological Safety Level): 1, 2
Services: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging
Category / Product: BIOLOGICS
OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 5,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 5,000 µg/day)
Markets: EMA (EU), FDA (USA)
Region: Europe
Batch Size: Large, Small, Medium
Use: Human
Services: Manufacturing services, Analytical / QC services, Quality Assurance services, Packaging
Therapeutic Areas of Expertise (ATC): (L) Antineoplastic and immunomodulating agents
Compliance: EMA (EU GMP)
Category / Product: FDF / DRUG PRODUCTS
Probio
Globalne GCT i leki biologiczne CDMO, przyspieszające proces przejścia od genu do rynku komercyjnego.
Region: APAC
Compliance: FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), EMA (EU GMP)
Batch Size: Large, Small, Medium
Use: Human
Category / Product: BIOLOGICS

53Biologics
53Biologics to hiszpańska CDMO specjalizująca się w dekodowaniu produkcji leków biologicznych, od DNA po białka.
Markets: EMA (EU), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), TGA (Australia)
Services: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services
Region: Europe
Compliance: FDA (cGMP), ISO, EMA (EU GMP), World Health Organization (GMP / HACCP)
Batch Size: Large, Small, Medium
Use: Human, Veterinary
BSL (Biological Safety Level): 1, 2
Category / Product: BIOLOGICS

BDI biotech
Pracujemy jako dział badawczo-rozwojowy specjalizujący się w opracowywaniu szczepów i bioprocesów, zwiększaniu skali i produkcji seryjnej.
Markets: EMA (EU), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), TGA (Australia)
Services: Logistics, Development services, Manufacturing services, Analytical / QC services, Regulatory services
Region: Europe
Compliance: ISO
BSL (Biological Safety Level): 1
Batch Size: Small, Medium
Category / Product: BIOLOGICS

Cultiply
Hiszpańskie CDMO, które opracowuje procesy produkcji i oczyszczania rekombinowanych białek, enzymów, DNA i innych produktów pochodzenia biologicznego.
Markets: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), MFDS (South Korea), CDSCO (India), TGA (Australia)
Region: Europe
Compliance: ISO
BSL (Biological Safety Level): 1, 2
Services: Development services, Manufacturing services
Controlled Substances: Lowest potential for abuse
Batch Size: Small, Medium
Category / Product: BIOLOGICS
OEB (Occupational Exposure Banding): 1 / low-hazard (PDE > 5,000 µg/day)

EVER Neuro Pharma GmbH
Specjalistyczne CDMO do opracowywania i produkcji małocząsteczkowych preparatów do wstrzykiwań.
OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 5,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 5,000 µg/day)
Controlled Substances: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, Lower potential for abuse
Markets: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, EDE (UAE), CDSCO (India), TGA (Australia), Reszta świata
Services: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging
Region: Europe
Compliance: ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), TITCK (Turkish Health Authorities), NMPA (China GMP), EMA (EU GMP), MFDS/KFDA (Republic of Korea GMP)
Batch Size: Large, Small, Medium
Use: Human
BSL (Biological Safety Level): 1, 2
Therapeutic Areas of Expertise (ATC): (H) Systemic hormonal preparations excl. sex hormones and insulins, (L) Antineoplastic and immunomodulating agents, (N) Nervous system
Category / Product: FDF / DRUG PRODUCTS
Zarejestruj się, aby odblokować pełny katalog z danymi kontaktowymi i lokalizacjami.
+103 więcej udogodnień
Utwórz darmowe kontoAre you a pharmaceutical company seeking a reliable CMO or CDMO partner to accelerate your drug development process? Look no further than MAI CDMO Network. Our advanced search platform connects you with a vast network of qualified contract manufacturers and development organizations worldwide.
Why Choose MAI CDMO Network?
How MAI CDMO Network Works
Key Benefits of Partnering with a CMO/CDMO
Featured Services
Ready to Find Your Ideal CMO/CDMO Partner? Register Now
Explore our platform today and discover how MAI CDMO Network can help you achieve your drug development goals.